Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
NDOR1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9UHB4 |
|---|---|
| Clone Names | 110617267 |
| Gene ID | 27158 |
|---|---|
| Other Names | NADPH-dependent diflavin oxidoreductase 1 {ECO:0000255|HAMAP-Rule:MF_03178}, 16-- {ECO:0000255|HAMAP-Rule:MF_03178}, NADPH-dependent FMN and FAD-containing oxidoreductase {ECO:0000255|HAMAP-Rule:MF_03178}, Novel reductase 1, NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178}, NR1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178} |
|---|---|
| Function | NADPH-dependent reductase which is a central component of the cytosolic iron-sulfur (Fe-S) protein assembly (CIA) machinery (PubMed:10625700, PubMed:28648056, PubMed:23596212, PubMed:20802492, PubMed:15900210). Transfers electrons from NADPH via its FAD and FMN prosthetic groups to the [2Fe-2S] cluster of CIAPIN1, another key component of the CIA machinery (PubMed:28648056, PubMed:23596212, PubMed:20802492). In turn, this reduced cluster provides electrons for assembly of cytosolic iron-sulfur cluster proteins (PubMed:23596212, PubMed:20802492). It can also reduce the [2Fe-2S] cluster of CISD1 and activate this protein implicated in Fe/S cluster repair (PubMed:28648056). In vitro can fully activate methionine synthase/MTR in the presence of soluble cytochrome b5/CYB5A (PubMed:12871938). |
| Cellular Location | Cytoplasm, perinuclear region {ECO:0000255|HAMAP- Rule:MF_03178, ECO:0000269|PubMed:10625700, ECO:0000269|PubMed:12871939}. Note=Concentrated in perinuclear structure. {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:12871939} |
| Tissue Location | Low expression in brain, heart, kidney, pancreas, prostate and skeletal muscle. Highest levels in the placenta. Expressed in cancer cell lines including promyelocytic leukemia, HeLaS3, chronic myelagenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, colorectal adenocarcinoma, lung carcinoma, and melanoma G-361 |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an NADPH-dependent diflavin reductasethat contains both flavin mononucleotide (FMN) and flavin adeninedinucleotide (FAD) binding domains. The encoded protein is anenzyme that catalyzes the transfers electrons from NADPH throughFAD and FMN cofactors to potential redox partners. Alternativesplicing results in multiple transcript variants. [provided byRefSeq].
References
Kwasnicka-Crawford, D.A., et al. Biochem. Biophys. Res. Commun. 336(2):565-571(2005)Finn, R.D., et al. Pharmacogenet. Genomics 15(6):381-386(2005)Kwasnicka, D.A., et al. J. Biol. Chem. 278(40):39051-39058(2003)Olteanu, H., et al. J. Biol. Chem. 278(40):38310-38314(2003)Finn, R.D., et al. Eur. J. Biochem. 270(6):1164-1175(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
